Our results demonstrated that melatonin, via its MT1 receptor, plays an inhibitory role in breast cancer cell invasion, possibly by specifically downregulating the p38 MAPK signaling pathway, and the downstream activity of MMP-2 and MMP-9. Here, MMP9 is linked to breast cancer.